The University of Cambridge received a $4,598,677 Project Grant from the Defense Health Agency to conduct research under the Military Medical Research and Development program (CFDA 12.420). The research aims to use multi-modal data integration across breast cancer molecular subtypes to develop predictors of treatment response, early relapse, and survival, as well as explore early signals of later metastatic recurrence. The 4-year grant, which began on September 1, 2023, leverages the University of Cambridge's expertise in scientific research to advance the program's objectives of transforming health care for service members and the public through innovative and impactful studies. As a prominent academic institution, the University of Cambridge often receives federal funding to support basic, applied, and advanced biomedical research activities relevant to agency missions.